Risultati per: Linee guida sul melanoma cutaneo

New England Journal of Medicine, Volume 387, Issue 23, Page 2113-2125, December 2022.

This cohort study investigates the association among different immunosuppressive regimens for grade 3 and higher immune-related adverse events with overall survival and progression-free survival in a homogeneous cohort of patients with advanced melanoma who were treated with first-line ipilimumab and nivolumab.

This economic evaluation aims to determine the cost-effectiveness of ipilimumab discontinuation for patients with interim imaging-confirmed tumor response in the treatment of advanced melanoma.

This cohort study aims to identify lifetime trajectories of sunburns and compare the association between these trajectories and subsequent risk of cutaneous melanoma and squamous cell carcinoma.